May-Hegglin anomaly 1,2 (MHA) is an autosomal dominant macrothrombocytopenia of unclear pathogenesis characterized by thrombocytopenia, giant platelets and leukocyte inclusions. Studies have indicated that platelet structure and function are normal 3-7 , suggesting a defect in megakaryocyte fragmentation 8 . The disorder has been linked to chromosome 22q12-13. Here we screen a candidate gene in this region, encoding nonmuscle myosin heavy chain A (MYH9), for mutations in ten families. In each family, we identified one of three sequence variants within either the α-helical coiled coil or the tailpiece domain that co-segregated with disease status. The E1841K mutation was found in 5 families and occurs at a conserved site in the rod domain. This mutation was not found in 40 normal individuals. Four families had a nonsense mutation that resulted in truncation of most of the tailpiece. One family had a T1155I mutation present in an affected mother and daughter, but not in the mother's parents, thus representing a new mutation. Among the 30 affected individuals, 21 unaffected individuals and 13 spouses in the 10 families, there was correlation of a variant of MYH9 with the presence of MHA. The identification of MYH9 as the disease gene for MHA establishes the pathogenesis of the disorder, should provide further insight into the processes of normal platelet formation and may facilitate identification of the genetic basis of related disorders.
May-Hegglin anomaly 1,2 (MHA) is an autosomal dominant macrothrombocytopenia of unclear pathogenesis characterized by thrombocytopenia, giant platelets and leukocyte inclusions. Studies have indicated that platelet structure and function are normal [3] [4] [5] [6] [7] , suggesting a defect in megakaryocyte fragmentation 8 . The disorder has been linked to chromosome 22q12-13. Here we screen a candidate gene in this region, encoding nonmuscle myosin heavy chain A (MYH9), for mutations in ten families. In each family, we identified one of three sequence variants within either the α-helical coiled coil or the tailpiece domain that co-segregated with disease status. The E1841K mutation was found in 5 families and occurs at a conserved site in the rod domain. This mutation was not found in 40 normal individuals. Four families had a nonsense mutation that resulted in truncation of most of the tailpiece. One family had a T1155I mutation present in an affected mother and daughter, but not in the mother's parents, thus representing a new mutation. Among the 30 affected individuals, 21 unaffected individuals and 13 spouses in the 10 families, there was correlation of a variant of MYH9 with the presence of MHA. The identification of MYH9 as the disease gene for MHA establishes the pathogenesis of the disorder, should provide further insight into the processes of normal platelet formation and may facilitate identification of the genetic basis of related disorders.
We and others have reported genetic linkage of MHA to chromosome 22q12-13 (refs 9-11). Among the 21 known genes within the minimal disease region from D22S683 to D22S1045, MYH9 accounts for approximately 2% of platelet protein content and was considered a likely candidate gene. We sequenced the 40 coding exons and adjacent splice regions of MYH9 using genomic DNA from 2 affected individuals (III-1 and III-16) of family MHA-1 (ref. 9). We detected a single heterozygous base pair change of G→A in exon 38 at nt 5,521 (G5521A) of the coding region of the cDNA (Fig. 1) , predicting a change from glutamine to lysine at amino acid 1,841 (E1841K). We confirmed this nucleotide change in individuals III-1 and III-16 of family MHA-1 using the loss of an RsrII restriction site (Fig. 1) . Each of 8 living affected individuals and none of 11 unaffected individuals or 4 spouses in this family ( Fig. 1) were heterozygous for G5521A. Affected individuals in four other families, MHA-6, MHA-8, MHA-13 and MHA-16, contained the G5521A nucleotide change. Using loss of the RsrII restriction site, we found that G5521A co-segregated with disease status in each of these families. We did not find the G5521A variant in 40 unrelated normal DNA samples.
Next, we sequenced the MYH9 coiled coil and tailpiece domains in five MHA families without the G5521A mutation. In affected individuals of four families (MHA-4, MHA-5, MHA-11 and MHA-14), we found a C→T transition in exon 40 at nucleotide position 5,797 of the coding region ( Fig. 1 ). This nucleotide change is a nonsense mutation in amino acid 1,933 of the protein (R1933Ter), resulting in truncation of 28 of 34 amino acids of the carboxy-terminal tailpiece of the myosin heavy chain. Gain of an MspA1I site confirmed the presence of this sequence change (Fig. 1) . We detected the G5521A mutation in all 11 affected individuals, but in none of 6 unaffected individuals or 4 spouses examined. Sequence analysis of affected individual III-2 of the remaining family, MHA-3 ( Fig. 2) , identified a C→T transition at nt 3,464 ( Fig. 1 ) resulting in a missense change from threonine to isoleucine at amino acid 1,155 (T1155I). The unaffected parents of individual II-2 of family MHA-3 did not carry this mutation (Fig. 2) . Haplotype analysis of chromosome 22 family: mutation:
RsrII: MspA1I: MspA1I: letter markers near MYH9 indicated that the disease haplotype was inherited from the father of individual II-2 ( Fig. 2) . Thus, individual II-2 represents a new mutation in MYH9 and confirms the association of the T1155I change with the phenotype. In summary, each of ten families had one of three MYH9 mutations (Table 1) . Genotype analysis did not reveal evidence of a founder effect. The conventional myosin heavy chains consist of two major domains: head and rod. The rod domain is composed of 40 repeats of 28 residues that are predicted to form an α-helical coiled coil. Both E1841K and T1155I mutations occur at conserved positions in the rod domain (Fig. 3) . The glutamic acid residue at position 1,841 is present in the thirty-seventh 28-residue repeat and is conserved across all known human conventional myosin heavy chains, except smooth muscle myosin heavy chain (encoded by MYH11), in which a similarly negatively charged aspartate residue fills this position. Non-muscle myosin heavy chains have also been conserved at this residue during evolution. The threonine at position 1,155 of MYH9 is in the twelfth 28-residue repeat and has been similarly conserved in conventional human myosin heavy chains and in vertebrate non-muscle myosin heavy chains (Fig. 3) .
Myosin heavy chains dimerize through the C-terminal α-helical coiled-coil domain. Alternating charged regions of exposed surfaces of the coiled-coil domain associate to form myosin filaments with a defined periodicity 12 . The non-conservative charge effect of the E1841K mutation may result in disruption of the intermolecular association of the myosin molecule, prohibiting filament assembly as was observed as a result of an arginine to aspartic acid mutation in the Dictyostelium discoideum type II myosin heavy chain 13 . The non-helical tailpiece has also been implicated in myosin filament assembly 14, 15 . Thus, both the alteration of charge (E1841K) mutation and the truncation of the tailpiece (R1933Ter) are expected to decrease myosin filament assembly, and may represent a common mechanistic explanation of MHA-associated mutations.
The known vertebrate conventional myosins include 11 isoforms 16 . The two non-muscle myosins (A and B) are widely and differentially expressed in tissues 17, 18 , and have overlapping but distinct intracellular localization 19, 20 , suggesting they have distinct functions. Deletion of the single D. discoideum non-muscle myosin heavy chain gene results in alteration of a number of common cellular functions including maintenance of cortical tension, capping of cell surface receptors, morphogenic changes in shape associated with developmental processes and cytokinesis 21, 22 . In humans, the limited abnormalities resulting from mutation of MYH9 in MHA may result from redundancy due to coexpression of non-muscle type B myosin in most tissues. Only type A is expressed in platelets, where myosin accounts for approximately 2% of total protein content.
Mutations of genes encoding myosin heavy chains have been implicated in other genetic disorders, such as hypertrophic cardiomyopathy type 1 (MIM 192600), hearing defects (DNFA11) and Usher syndrome 23, 24 . Our description of MYH9 mutations in MHA is the first report of naturally occurring mutations affecting the coiled-coil and tailpiece domain of a conventional myosin and may provide further insight into the function of this widely expressed molecule.
Methods
Families. We ascertained and characterized ten families with MHA as described 9 . Families MHA-1, MHA-4 and MHA-5 have been described 9 . The pedigree of family MHA-3 is shown in Fig. 2 . The total number of affected individuals in each family (and affected individuals studied for MYH9 mutations), total number of unaffected individuals (and unaffected individuals studied for MYH9 mutations) and total spouses (and spouses studied for MYH9) in each family were as follows: 10 ( respectively. All families were of European descent, except family MHA-4, which is of Hispanic origin. All affected individuals had characteristic haematologic findings of thrombocytopenia, giant platelets and leukocyte inclusions, whereas these findings were absent from unaffected relatives and unrelated control individuals 9 . No overt auditory or kidney disease was present in affected individuals from these families.
Mutation screening.
Oligonucleotide primers amplifying the 40 exons of MYH9 were designed using the sequence of chromosome 22 (ref. 25) . PCR products were purified using QIAQuick PCR Purification kit (Qiagen) and sequenced by BigDye terminator chemistry (Perkin-Elmer) on an ABI 310 (Perkin-Elmer) using either the oligonucleotide primers used for amplification or internal primers. Exons with coding regions more than ∼150 bp were sequenced on both strands. The sequence of oligonucleotide primers used to amplify and sequence exons 25, 38 and 40 were as follows: MYH9-25F, 5´-GCAAACTCTGCTCCTTGGAG-3´ and MYH9-25R, 5´-AGCCAG GTCCTTCAACAGAC-3´; MYH9-38F, 5´-GTCCTGGTTAGGGCTTG TTG-3´ and MYH9-38R, 5´-GTAGATGCCTTGTCGGCCTG-3´; MYH9-40F, 5´-TTGCTTCTTTCTGGTGGGAG-3´ and MYH9-40R, 5´-ACAGCA GTCCCAAGAAGGTG-3´. A list of all oligonucleotide primers used is available on request. 183  187  166  174  C  C  C  C  218  218  164  160  155  152  117  121   191  195  196  192   218  218  156  156  149  155  117  117   D22S685  D22S683  MYH9-3464  D22S426  D22S692  D22S1045  D22S445   179  194  176  172  C  C  T  C  214  216  160  164  149  155  113  117   183  191  166  196   218  218  164  156  155  149  117 
